AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05691088 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paracetamol injection
Description: Patients were randomized to receive either paracetamol during mechanical ventilation. When patients were randomized to receive paracetamol (40 mg/kg per day in 4 doses), a placebo infusion of normal saline was administered continuously at the same rate as an equivalent infusion. Placebos could not be distinguished from the active study drug in color, odor, or viscosity.~In both study groups, IMV was maintained with sufentanil (0-0.2 mcg/kg/h), propofol (0-4 mg/kg/h), and dexmedetomidine (0-1 mcg/kg/h). Assessment of sedation levels by the bedside nurse using the FLACC pain scale to determine if the child is adequately comfortable or in need of more or less medication to maintain adequate ventilation. Assessment of sedation levels by the bedside nurse using the FLACC pain scale (every 6 hours as a minimum time interval).
Study NCT05600543 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumbar belt
Description: All subjects (LBP group and healthy group) wear the belt during the two visits to perform differents tests.~The invistigator will ask the LBP patients to wear the lumbar belt between the two visits (for 4 weeks, for 4 to 8 hours per day)
Study NCT05600543 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lombaskin lumbar belt and the Lyne Up percko postural T-shirt.
Description: Lombaskin lumbar belt and the Lyne Up percko postural T-shirt could be worn during the third addtional visit proposed to the healthy subject.
Study NCT06112002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Attend an educational session
Study NCT06112002 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: Receive educational materials
Study NCT06112002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT05456555 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flapless with Enamel Matrix Derivatives (EMD)
Description: Experimental sites will receive a closed non-surgical treatment with a combined use of minicurettes and ultrasonic instruments with thin and delicate tips. Teeth will be instrumented until no residual calculus could be detected. A visualization of the root surface will be accomplished under magnification by using dental loups 4.0X. In the test group, the roots will be conditioned with 24% ethylenediaminetetraacetic acid (EDTA) for 2 minutes. After rinsing with sterile saline, enamel matrix derivatives (EMD) will be applied on the dried root surface.
Study NCT05456555 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flapless without Enamel Matrix Derivatives (EMD)
Description: Experimental sites will receive a closed non-surgical treatment with a combined use of minicurettes and ultrasonic instruments with thin and delicate tips. Teeth will be instrumented until no residual calculus could be detected. A visualization of the root surface will be accomplished under magnification by using dental loups 4.0X. No adjunct will be administered.
Study NCT05005312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07321332
Description: Tablet
Study NCT05005312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: PK Boosting agent
Study NCT06043089 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beetroot juice supplementation or placebo
Description: Athletes received 7 days of beetroot juice supplementation with nitrate supplementation (2 × 70 mL of beetroot juice ∼12.9 mmol NO3-; Beet It, James White Drinks, Ipswich, UK) or placebo (2 × 70 mL of water with beetroot powder with negligible nitrate content).
Study NCT05608889 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Total Worker Health Mindfulness Enhanced Program
Description: The intervention will be delivered during 12, 45-minute weekly meetings of Correctional Professionals while on shift. Those sessions will be a combination of a video, mindfulness activity, and a group learning activity. It will conclude with members stating personal goals that will be followed up at the next meeting.~Sessions will be scripted to make them easy to implement with high fidelity, and include tasks, learning activities, and wrap-up with practice instructions for each week. Coworkers will be responsible for running the sessions, which promotes shared norms and social support.
Study NCT06475248 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inhibition of the suboccipital
Description: Inhibition of the suboccipital: the participant is in the supine position, the researcher will position himself behind the patients head. In this technique, contacts will be made on the suboccipital area with the 2nd, 3rd and 4th fingers of both hands. Make a slight pull with your body backwards and wait that there is relaxation of muscular tensions.
Study NCT06455540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Superior hypogastric plexus block
Description: Prior to the laparoscopic hysterectomy and any additional procedures, the superior hypogastric plexus block will be performed on all the patients. The block will contain 20 mL of 0.75% ropivacaine hydrochloride or 0.9% normal saline. The injection will be performed by tenting the presacral peritoneum, aspirating with a laparoscopic needle-tip syringe to ensure extravascular placement, and injecting the block.
Study NCT06455540 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Superior hypogastric plexus block
Description: Prior to the laparoscopic hysterectomy and any additional procedures, the superior hypogastric plexus block will be performed on all the patients. The block will contain 20 mL of 0.75% ropivacaine hydrochloride or 0.9% normal saline. The injection will be performed by tenting the presacral peritoneum, aspirating with a laparoscopic needle-tip syringe to ensure extravascular placement, and injecting the block.
Study NCT06500169 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06500169 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Discussion
Description: Ancillary studies
Study NCT06500169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Complete golf related exercises
Study NCT06500169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies
Study NCT06500169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear activity tracker
Study NCT06500169 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Examination
Description: Ancillary studies
Study NCT06500169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Performance Testing
Description: Ancillary studies
Study NCT06500169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06500169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recreational Therapy
Description: Participate in golf program
Study NCT06439147 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: U shaped capsular incision during capsulorrhaphy
Description: Incision of the capsule of the hip during open reduction of Developmental Dysplasia of the Hip,Incision is done with its base proximally. The transverse limb is 1 cm proximal to femoral neck base
Study NCT06439147 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: T-shaped capsular incision diuring capsulorraphy
Description: Incision of the capsule of the hip during open reduction of Developmental Dysplasia of the Hip done by two incisions: Vertical limb parallel to femoral neck axis and a transverse one parallel to the inguinal ligament resulting into two flabs.
Study NCT06129825 — intervention group
Intervention type: OTHER
Intervention: Prospective
Description: Single arm, healthy adult volunteers for blood donation.
Study NCT06456905 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Participants in the contingent group will be rewarded on an incrementally increasing scale for submitting consecutive breathalyzer samples that are 0.00%. For every day this target is met, the participant will receive an increase in reward until a daily cap is reached. If a day contains at least one sample where the target is not met, the participant will not be paid for that day, and the amount will reset. The participant will have the opportunity to earn on this scale throughout the duration of the study.
Study NCT04673942 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdAPT-001
Description: Oncolytic virus administered by intratumoral injection
Study NCT04673942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Checkpoint Inhibitor, Immune
Description: Checkpoint Inhibitor per investigator discretion based on diagnosis and subject tolerability
Study NCT02864888 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Children with a diffuse, intrinsic brain stem glioma will receive radiation.
Study NCT02864888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atengenal
Description: Children with a diffuse, intrinsic brain stem glioma will receive Atengenal in combination with Astugenal (Antineoplaston therapy) and radiation
Study NCT02864888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astugenal
Description: Children with a diffuse, intrinsic brain stem glioma will receive Astugenal in combination with Atengenal (Antineoplaston therapy) and radiation
Study NCT04473066 — intervention group
Intervention type: PROCEDURE
Intervention: Adenotonsillectomoy +/- turbinate reduction
Description: Tonsillectomies were performed by bipolar electrocautery while adenoidectomies were done by monopolar suction diathermy. Turbinate reduction (by either submucosal bipolar diathermy or radiofrequency) would be offered if the subject had on-going history of allergic rhinitis and examination revealed at least grade II turbinate hypertrophy. (Grade I = no turbinate hypertrophy; Grade II = turbinate hypertrophy without touching the septum; Grade III = turbinate hypertrophy touching the septum).
Study NCT05656872 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transverse Abdominis Plane Block
Description: Group T, will be performed in a supine position after skin sterilization, a linear high-frequency transducer Siemens acuson x300 3-5 MHZ will be placed in the transverse plane to the lateral abdominal wall in the mid-axillary line, between the lower costal margin and iliac crest. The abdominal wall muscles (external oblique, internal oblique, and transversus abdominis) will be visualized. A blunt tip,20-gauge, short bevel needle(Pajunk Sonoplex, Germany) will be inserted in-plane and advanced anterior to posterior under continuous visualization until the tip reaches between the internal oblique and the transversus abdominis muscle. After negative aspiration, 20 mL of bupivacaine 0.25%, lidocaine 1% will be injected. Separation of the internal oblique and transversus abdominis with a distinct pocket of local anesthetic in-between will be observed. The procedure will be repeated following the same steps on the other side.
Study NCT05656872 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ilioinguinal-iliohypogastric block
Description: Group I, will receive an Ultrasound-guided IIIH block that will be performed in a supine position after skin sterilization, a linear high-frequency transducer Siemens acuson x300 3-5 MHZ will be placed on the line between the anterior superior iliac spine and the umbilicus, where 3 layers of muscles (extra-abdominal oblique, intra-abdominal oblique, and transverse abdominis) will be visible on the inner side of the anterior superior iliac spine.A blunt tip,20-gauge, short bevel needle(Pajunk Sonoplex, Germany) will be inserted in-plane and advanced anterior to posterior under continuous visualization until the tip reaches between the internal oblique and the transversus abdominis muscle next to the iliohypogastric/ilioinguinal nerve. After negative aspiration, 20 mL of bupivacaine 0.25%, lidocaine 1% will be injected. The procedure will be repeated following the same steps on the other side.
Study NCT06484686 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Attenuated Varicella Vaccine
Description: lyophilized powder, subcutaneous injection
Study NCT05516836 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multicomponent exercise program
Description: Each exercise session will have a duration of forty minutes in which the thirty minutes of intervallic work will be distributed as follows: twenty seconds until reaching 60% of their maximum load in the first seven sessions, adding five watts each day until reaching 80% of their maximum load in the fourteen sessions and seventy seconds of rest at 20% of their maximum load.~At the end of the sessions, strengthening exercises will be performed with elastic bands, adapting their resistance according to the characteristics of the patients, of the lower limbs and of the upper limbs. Individualized respiratory physiotherapy exercises (diaphragmatic stimulation, positive expiratory pressure exercises, alveolar retraining and strengthening of the inspiratory musculature) will also be performed.
Study NCT05516836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise program
Description: Each exercise session will have a duration of forty minutes in which the thirty minutes of intervallic work will be distributed as follows: twenty seconds until reaching 60% of their maximum load in the first seven sessions, adding five watts each day until reaching 80% of their maximum load in the fourteen sessions and seventy seconds of rest at 20% of their maximum load.~At the end of the sessions, strengthening exercises will be performed with elastic bands, adapting their resistance according to the characteristics of the patients, of the lower limbs and of the upper limbs. Individualized respiratory physiotherapy exercises (diaphragmatic stimulation, positive expiratory pressure exercises, alveolar retraining and strengthening of the inspiratory musculature) will also be performed.
Study NCT05516836 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-health primary care rehabilitation program
Description: A once a week telemedicine session will be carried out with the case group only before the face-to-face sessions, consisting of education, respiratory exercise, mobility and stretching, giving them a place to provide feedback and re-evaluate patients mid-treatment and will be aimed at assessing improvement and improving therapeutic adherence.
Study NCT06343636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VG-3927
Description: Dose Escalation
Study NCT06343636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose Escalation
Study NCT06343636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VG-3927
Description: One Dose Level
Study NCT04532424 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: Non-invasive brain stimulation technique that is FDA-approved for the treatment of refractory depression, OCD and migraine.
Study NCT03994887 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: EEG acquisition system BioSemi (Amsterdam, the Netherlands), enabling real-time measurement and continuous recording of EEG on up to 128 leads.
Study NCT04999215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-choline intravenous injection
Description: Participants will receive one injection of F-choline before undergoing hybrid PET/CT imaging per standard procedures. F-choline PET examinations may be repeated, if this judged to be in the patient's best interest by his referring physician and the study staff, up to a maximum 4 examinations per year.
Study NCT05629065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinician Nudge Email
Description: -Clinician nudge email encouraging discussion to initiate discussion on SIC at next visit
Study NCT05629065 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Nudge Letter and Share questionaire
Description: Involves patient nudge consists of a letter and SHARE questionnaire~- patient nudge is a letter and a SHARE questionnaire encourages the participant to complete the SHARE questionnaire, which asks questions about the participants goals and preferences around cancer care, and discuss the questionnaire with their oncology clinician at the next visit.
Study NCT05538312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vepdegestrant
Description: Participants will receive a single dose of vepdegestrant by mouth in Period 1 and Period 2, with a washout period of at least 10 days between doses of vepdegestrant
Study NCT05538312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Participants will receive itraconazole by mouth once a day for 11 days in Period 2.
Study NCT06440967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fezolinetant
Description: oral
Study NCT06440967 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT06440967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: oral
Study NCT06440967 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tamoxifen
Description: oral
Study NCT06440967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor
Description: oral
Study NCT06440967 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aromatase inhibitor
Description: oral
Study NCT06057935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Possible substitution with carboplatin based on clinician discretion
Study NCT06097533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabisextrakt Avextra 10/10 Lösung
Description: medical cannabinoids
Study NCT06097533 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabisextrakt Avextra 10/10 Lösung
Description: medical cannabinoids
Study NCT05787587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDE-161
Description: Oral Medication
Study NCT06215040 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic retrograde cholangiopancratography
Description: common bile duct stone removal
Study NCT05721326 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sequential EHR Communications
Description: The intervention includes 3 message types: an EHR message, followed by a text message, followed by physician nudge. Each subsequent type will be activated if the previous type does not yield a response.
Study NCT06354309 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality game
Description: Pre and post control study after use virtual reality game
Study NCT05875168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-3939a
Description: One IV infusion Q3W on Day 1 of each 21-day cycle
Study NCT06128200 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NEUROMARK System
Description: The NEUROMARK System is indicated for use in otorhinolaryngology (ENT) surgery for creation of radiofrequency (RF) lesions to disrupt posterior nasal nerves in patients with chronic rhinitis.
Study NCT06128200 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham NEUROMARK System
Description: Sham ablation procedure using the NEUROMARK System
Study NCT05702853 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-CD34t metabolically programmed CAR transduced T-cells
Description: Cells are to be infused intravenously (IV) over 30 minutes or less via nonfiltered tubing either by gravity or a peristaltic pump, gently agitating the bag during infusion to prevent cell clumping
Study NCT06640725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab administration at 10mg/kg
Description: Maintenance (until progression, unacceptable toxicity or if CR \&gt; 1 year, as per investigator choice)~Avelumab 10 mg/kg every 2 weeks (±3 days)
Study NCT06640725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab (Erbitux)
Description: Maintenance (until progression, unacceptable toxicity or if CR \&gt; 1 year, as per investigator choice)~Cetuximab 500 mg/m² every 2 weeks (±3 days) (according to current recommendations \[35\])
Study NCT05189925 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp91 Grans
Description: Adults with gp91phox-deficient CGD without systemic infection will participate in a dose escalation trial to identify the MTD (the most effective yet safe dose) of gp91 Grans IV infusion.
Study NCT05276973 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT04811716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pozelimab
Description: Administered Sub-cutaneous (SC) per protocol
Study NCT04811716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemdisiran
Description: Administered SC per protocol
Study NCT05276973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT05276973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Given PO
Study NCT05276973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT06636357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50% N2O plus 50% O2
Description: Inhalation of 50% N2O plus 50% O2 for 45 min
Study NCT06636357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen (O2)
Description: 50% O2 plus 50% air for 45 min
Study NCT06263673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: 100 mg once daily, oral